AVALO THERAPEUTICS, INC. Finite-lived Intangible Assets Acquired
AVALO THERAPEUTICS, INC. (AVTX) reported Finite-lived Intangible Assets Acquired of $900.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-02.
Discontinued › Notes › Goodwill and Other
us-gaap:FinitelivedIntangibleAssetsAcquired1 · last filed 2022-03-02
- AVALO THERAPEUTICS, INC. finite-lived intangible assets acquired for fiscal 2020 was $900.00K.
- AVALO THERAPEUTICS, INC. finite-lived intangible assets acquired for fiscal 2018 was $150.00K, a 99.17% decline from fiscal 2017.
- AVALO THERAPEUTICS, INC. finite-lived intangible assets acquired for fiscal 2017 was $18.07M.
| Period end | Finite-lived Intangible Assets Acquired 12 month | Finite-lived Intangible Assets Acquired 12 month as first filed |
|---|---|---|
| 2020-12-31 | $900.00K 10-K · filed 2022-03-02 | |
| 2018-12-31 | $150.00K 10-K · filed 2020-03-11 | $18.44M 10-K · filed 2019-03-18 |
| 2017-12-31 | $18.07M 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |